30
Nov
2008
Posted in I - Series B, Q - 2Q08, R - WEST, X - Opthalmology, X - RNAi, X - Renal
Quark Pharmaceuticals (Fremont, CA) development-stage pharmaceutical company focused on discovering and developing novel RNAi therapeutics, closed a $27M Series B financing. Participants include SBI Investment Co.